Articles Vol. 65 No. CĐ 3 - Bệnh viện Phổi Trung ương 15/05/2024

39. NON-SMALL CELL LUNG CANCER WITH SIMULTANEOUS EGFR AND PIK3CA GENE MUTATIONS: PRELIMINARY TREATMENT RESULTS AT NATIONAL LUNG HOSPITAL FROM 2022 TO 2024

Le Tu Linh1,2,3,4, Dinh Van Luong1,2,3,4, Dang Duy Hieu2,4, Nguyen Doan Trang2,4, Nguyen Viet Anh2,4, Do Quang Duy2,4, Nguyen Viet Nhung5,6, Pham Quang Anh7,8, Nguyen Thi Trang2,4
1 National Lung Hospital
2 Hanoi Medical University
3 Bệnh viện Phổi Trung ương
4 Đại học Y Hà Nội
5 University of Medicine and Pharmacy - Vietnam National University
6 Trường Đại học Y dược-ĐH Quốc Gia Hà Nội
7 Thai Binh Medical University
8 Đại học Y Thái Bình
Corresponding author: Trangnguyen@hmu.edu.vn
DOI: 10.52163/yhc.v65iCD3.1136
16 Views
9 Downloads
Keywords
Non-small cell lung cancer (NCSLS), co-mutation, EGFR, PIK3CA, EGFR TKI, initial treatment.
Abstract

Introduction: Targeted therapy treatment in non-small cell lung cancer patients significantly improves survival and quality of life for patients with EGFR mutations The coexistence of EGFR/PIK3CA mutations is considered a factor affecting the efficacy of EGFR-TKIs treatment in patients with non-small cell lung cancer (NCSLS).

Methods: The cross-sectional descriptive study was conducted on 6 patients with concurrent EGFR and PIK3CA mutations at the National Lung Hospital.

Results: 6/8 patients (75%) had EGFR Del19 mutations, 2/8 patients had L858R mutation. The mean age of the study group was 63.4 years, with 3 male patients (37.5%) and 5 female patients (62.5%). 4/8 patients (50%) had PIK3CA exon 9 mutations, 2/8 patients (25%) had PIK3CA exon 4 mutation. The remaining 2 patients respectively carried PIK3CA exon 2 and exon 20 mutations. The median progression-free survival (PFS) was 10.2 months and overall response rate (ORR) was 62,5%, with 2/8 patients (25%) becoming resistant and treated with second-line chemotherapy and palliative care. There were no serious adverse effects in these patients.

Conclusion: The use of EGFR-TKIs as first-line treatment was effective in this group of EGFR/ PIK3CA co-mutated patients.

References
[1]
D. S. Ettinger et al., Non-Small Cell Lung Cancer, Google Scholar
[2]
Version 3.2022, NCCN Clinical Practice Google Scholar
[3]
Guidelines in Oncology, J. Natl. Compr. Cancer Google Scholar
[4]
Netw. JNCCN, vol. 20, no. 5, pp. 497–530, May Google Scholar
[5]
, doi: 10.6004/jnccn.2022.0025. Google Scholar
[6]
X. Liu, W. Mei, P. Zhang et al., PIK3CA mutation Google Scholar
[7]
as an acquired resistance driver to EGFR-TKIs in non- Google Scholar
[8]
small cell lung cancer: Clinical challenges and opportunities, Google Scholar
[9]
Pharmacol. Res.,vol. 202, p. 107123, Apr. 2024, doi: 10.1016/j. Google Scholar
[10]
phrs.2024.107123. Google Scholar
[11]
S.-G. Wu, Y.-L. Chang, C.-J. Yu et al., The Role Google Scholar
[12]
of PIK3CA Mutations among Lung Adenocarcinoma Google Scholar
[13]
Patients with Primary and Acquired Resistance to Google Scholar
[14]
EGFR Tyrosine Kinase Inhibition, Sci.Rep., vol. 6, p. 35249, Google Scholar
[15]
Oct. 2016, doi: 10.1038/srep35249. Google Scholar
[16]
M. Scheffler et al., PIK3CA mutations in nonsmall cell Google Scholar
[17]
lung cancer (NSCLC): Genetic heterogeneity, prognostic Google Scholar
[18]
impact and incidence of prior malignancies, Oncotarget, Google Scholar
[19]
vol. 6, no. 2, pp. 1315–1326, Jan. 2015, doi: 10.18632/ Google Scholar
[20]
oncotarget.2834. Google Scholar
[21]
C. Jing et al., Next-generation sequencing-based Google Scholar
[22]
detection of EGFR, KRAS, BRAF, NRAS, PIK- Google Scholar
[23]
CA, Her-2 and TP53 mutations in patients with Google Scholar
[24]
non-small cell lung cancer, Mol. Med. Rep., Google Scholar
[25]
vol. 18, no. 2, pp. 2191–2197, Aug. 2018, doi: Google Scholar
[26]
3892/mmr.2018.9210. Google Scholar
[27]
Liang N., Liu Y., Liu L. et al., Co-mutation of Google Scholar
[28]
PIK3CA and Other Oncogenes in Patients with Google Scholar
[29]
Non-small Cell Lung Cancer, 协和医学杂 Google Scholar
[30]
志, vol. 6, no. 3, pp. 186–190, May 2015, doi: Google Scholar
[31]
3969/j.issn.1674-9081.2015.03.005. Google Scholar
[32]
“Activating mutations in EGFR and PI3K promote Google Scholar
[33]
ATF4 induction for NSCLC cell survival during amino acid Google Scholar
[34]
deprivation - PubMed.”Accessed: Apr. 01, 2024. [Online]. Google Scholar
[35]
Available: Https://pubmed.ncbi.nlm.nih.gov/37025861/ Google Scholar
[36]
J.-Y. Chen et al., Predictive value of K-ras and Google Scholar
[37]
PIK3CA in non-small cell lung cancer patients Google Scholar
[38]
treated with EGFR-TKIs: A systemic review Google Scholar
[39]
and meta-analysis, Cancer Biol. Med., vol. 12, Google Scholar
[40]
no. 2, pp. 126–139, Jun. 2015, doi: 10.7497/j. Google Scholar
[41]
issn.2095-3941.2015.0021. Google Scholar